CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
unacelyated ghrelindrug
Likely dose
Unacylated ghrelin 10 μg/kg, 20 μg/kg, and 40 μg/kg on three separate daysAI-extracted
Key inclusion· 1
  • ✓Age 55 years or older with peripheral artery disease (PAD)
Key exclusion· 11
  • ✕Above or below-knee amputation
  • ✕Critical limb ischemia
  • ✕Wheelchair confinement
  • ✕Cardiovascular event in previous 3 months (exception: prior coronary revascularization may qualify)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03358355
NCT03358355Phase 2Completed
CompareCT.gov

Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial

Northwestern University·interventional·Posted Nov 30, 2017·Updated Mar 12, 2020

In Brief

A Phase 2 clinical trial evaluating unacelyated ghrelin for Peripheral Artery Disease and 2 related conditions. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The GIFT pilot study will investigate the optimal subcutaneous dose and safety of subcutaneously administered unacylated ghrelin in older people with peripheral artery disease (PAD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Artery Disease, PAD, Peripheral Arterial Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 30, 2017
Enrollment StartJun 7, 2016
Primary CompletionAug 30, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.6 years ago

Interventions

unacelyated ghrelindrug

We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.